The LSX Nordic Congress 2026 narrative presents a compelling case for the resilience and adaptability of Nordic biotech, but it also invites scrutiny of the underlying assumptions and potential blind spots. The strongest version of this story is that Nordic companies are leveraging their collaborative ecosystems and scientific specialization to compete globally, despite funding constraints. However, the emphasis on early partnerships and international scaling raises questions about long-term aut...